Cargando…

Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2

BACKGROUND: Multiparametric MRI (mp‐MRI) combined with machine‐aided approaches have shown high accuracy and sensitivity in prostate cancer (PCa) diagnosis. However, radiomics‐based analysis has not been thoroughly compared with Prostate Imaging and Reporting and Data System version 2 (PI‐RADS v2) s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tong, Li, Mengjuan, Gu, Yuefan, Zhang, Yueyue, Yang, Shuo, Wei, Chaogang, Wu, Jiangfen, Li, Xin, Zhao, Wenlu, Shen, Junkang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620601/
https://www.ncbi.nlm.nih.gov/pubmed/30230108
http://dx.doi.org/10.1002/jmri.26243
_version_ 1783434079014748160
author Chen, Tong
Li, Mengjuan
Gu, Yuefan
Zhang, Yueyue
Yang, Shuo
Wei, Chaogang
Wu, Jiangfen
Li, Xin
Zhao, Wenlu
Shen, Junkang
author_facet Chen, Tong
Li, Mengjuan
Gu, Yuefan
Zhang, Yueyue
Yang, Shuo
Wei, Chaogang
Wu, Jiangfen
Li, Xin
Zhao, Wenlu
Shen, Junkang
author_sort Chen, Tong
collection PubMed
description BACKGROUND: Multiparametric MRI (mp‐MRI) combined with machine‐aided approaches have shown high accuracy and sensitivity in prostate cancer (PCa) diagnosis. However, radiomics‐based analysis has not been thoroughly compared with Prostate Imaging and Reporting and Data System version 2 (PI‐RADS v2) scores. PURPOSE: To develop and validate a radiomics‐based model for differentiating PCa and assessing its aggressiveness compared with PI‐RADS v2 scores. STUDY TYPE: Retrospective. POPULATION: In all, 182 patients with biopsy‐proven PCa and 199 patients with a biopsy‐proven absence of cancer were enrolled in our study. FIELD STRENGTH/SEQUENCE: Conventional and diffusion‐weighted MR images (b values = 0, 1000 sec/mm(2)) were acquired on a 3.0T MR scanner. ASSESSMENT: A total of 396 features and 385 features were extracted from apparent diffusion coefficient (ADC) images and T(2)WI, respectively. A predictive model was constructed for differentiating PCa from non‐PCa and high‐grade from low‐grade PCa. The diagnostic performance of each radiomics‐based model was compared with that of the PI‐RADS v2 scores. STATISTICAL TESTS: A radiomics‐based predictive model was constructed by logistic regression analysis. 70% of the patients were assigned to the training group, and the remaining were assigned to the validation group. The diagnostic efficacy was analyzed with receiver operating characteristic (ROC) in both the training and validation groups. RESULTS: For PCa versus non‐PCa, the validation model had an area under the ROC curve (AUC) of 0.985, 0.982, and 0.999 with T(2)WI, ADC, and T(2)WI&ADC features, respectively. For low‐grade versus high‐grade PCa, the validation model had an AUC of 0.865, 0.888, and 0.93 with T(2)WI, ADC, and T(2)WI&ADC features, respectively. PI‐RADS v2 had an AUC of 0.867 in differentiating PCa from non‐PCa and an AUC of 0.763 in differentiating high‐grade from low‐grade PCa. DATA CONCLUSION: Both the T(2)WI‐ and ADC‐based radiomics models showed high diagnostic efficacy and outperformed the PI‐RADS v2 scores in distinguishing cancerous vs. noncancerous prostate tissue and high‐grade vs. low‐grade PCa. Level of Evidence: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:875–884.
format Online
Article
Text
id pubmed-6620601
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66206012019-07-22 Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2 Chen, Tong Li, Mengjuan Gu, Yuefan Zhang, Yueyue Yang, Shuo Wei, Chaogang Wu, Jiangfen Li, Xin Zhao, Wenlu Shen, Junkang J Magn Reson Imaging Original Research BACKGROUND: Multiparametric MRI (mp‐MRI) combined with machine‐aided approaches have shown high accuracy and sensitivity in prostate cancer (PCa) diagnosis. However, radiomics‐based analysis has not been thoroughly compared with Prostate Imaging and Reporting and Data System version 2 (PI‐RADS v2) scores. PURPOSE: To develop and validate a radiomics‐based model for differentiating PCa and assessing its aggressiveness compared with PI‐RADS v2 scores. STUDY TYPE: Retrospective. POPULATION: In all, 182 patients with biopsy‐proven PCa and 199 patients with a biopsy‐proven absence of cancer were enrolled in our study. FIELD STRENGTH/SEQUENCE: Conventional and diffusion‐weighted MR images (b values = 0, 1000 sec/mm(2)) were acquired on a 3.0T MR scanner. ASSESSMENT: A total of 396 features and 385 features were extracted from apparent diffusion coefficient (ADC) images and T(2)WI, respectively. A predictive model was constructed for differentiating PCa from non‐PCa and high‐grade from low‐grade PCa. The diagnostic performance of each radiomics‐based model was compared with that of the PI‐RADS v2 scores. STATISTICAL TESTS: A radiomics‐based predictive model was constructed by logistic regression analysis. 70% of the patients were assigned to the training group, and the remaining were assigned to the validation group. The diagnostic efficacy was analyzed with receiver operating characteristic (ROC) in both the training and validation groups. RESULTS: For PCa versus non‐PCa, the validation model had an area under the ROC curve (AUC) of 0.985, 0.982, and 0.999 with T(2)WI, ADC, and T(2)WI&ADC features, respectively. For low‐grade versus high‐grade PCa, the validation model had an AUC of 0.865, 0.888, and 0.93 with T(2)WI, ADC, and T(2)WI&ADC features, respectively. PI‐RADS v2 had an AUC of 0.867 in differentiating PCa from non‐PCa and an AUC of 0.763 in differentiating high‐grade from low‐grade PCa. DATA CONCLUSION: Both the T(2)WI‐ and ADC‐based radiomics models showed high diagnostic efficacy and outperformed the PI‐RADS v2 scores in distinguishing cancerous vs. noncancerous prostate tissue and high‐grade vs. low‐grade PCa. Level of Evidence: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:875–884. John Wiley and Sons Inc. 2018-09-19 2019-03 /pmc/articles/PMC6620601/ /pubmed/30230108 http://dx.doi.org/10.1002/jmri.26243 Text en © 2018 The Authors Journal of Magnetic Resonance Imaging published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Chen, Tong
Li, Mengjuan
Gu, Yuefan
Zhang, Yueyue
Yang, Shuo
Wei, Chaogang
Wu, Jiangfen
Li, Xin
Zhao, Wenlu
Shen, Junkang
Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
title Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
title_full Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
title_fullStr Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
title_full_unstemmed Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
title_short Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
title_sort prostate cancer differentiation and aggressiveness: assessment with a radiomic‐based model vs. pi‐rads v2
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620601/
https://www.ncbi.nlm.nih.gov/pubmed/30230108
http://dx.doi.org/10.1002/jmri.26243
work_keys_str_mv AT chentong prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT limengjuan prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT guyuefan prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT zhangyueyue prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT yangshuo prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT weichaogang prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT wujiangfen prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT lixin prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT zhaowenlu prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2
AT shenjunkang prostatecancerdifferentiationandaggressivenessassessmentwitharadiomicbasedmodelvspiradsv2